VYNE THERAPEUTICS
VYNE Therapeutics is a clinical late-stage biopharmaceutical company that focuses on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis, and prurigo nodularis.
VYNE THERAPEUTICS
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.vynetherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(650)486-1416
Email Addresses:
[email protected]
Total Funding:
297.84 M USD
Technology used in webpage:
Euro Cloudflare Hosting Getty Images
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Southern Scripts
Southern Scripts is the complexities of navigating through the Pharmacy Benefit Manager world by giving the employer group complete freedom.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuC™ platform.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-03-09 | Foamix | Foamix acquired by VYNE Therapeutics | N/A |
Investors List
Palo Alto Investors
Palo Alto Investors investment in Post-IPO Equity - VYNE Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - VYNE Therapeutics
Soleus Capital
Soleus Capital investment in Post-IPO Equity - VYNE Therapeutics
Eventide
Eventide investment in Post-IPO Equity - VYNE Therapeutics
Access Biotechnology
Access Biotechnology investment in Post-IPO Equity - VYNE Therapeutics
Parkman Healthcare Partners
Parkman Healthcare Partners investment in Post-IPO Equity - VYNE Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - VYNE Therapeutics
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - VYNE Therapeutics
Remeditex Ventures
Remeditex Ventures investment in Series C - VYNE Therapeutics
Presidio Partners
Presidio Partners investment in Series C - VYNE Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-09 | VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development |
Official Site Inspections
http://www.vynetherapeutics.com Semrush global rank: 4.81 M Semrush visits lastest month: 1.84 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "VYNE Therapeutics"
VYNE Therapeutics – Rooted in Innovation
VYNE Therapeutics ® is working to solve some of today’s most difficult therapeutic challenges. With every problem we take on, our approach is the same: question traditional assumptions …See details»
About Us – VYNE Therapeutics
Improving the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. VYNE Therapeutics ® is working to solve some of today’s most difficult …See details»
Our Mission – VYNE Therapeutics
VYNE Therapeutics ® is working to solve some of today’s most difficult therapeutic challenges. With every problem we take on, our approach is the same: question traditional assumptions …See details»
VYNE Therapeutics Inc. | LinkedIn
For every therapeutic challenge, we question traditional assumptions and find better solutions. | VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing...See details»
VYNE Therapeutics Inc. (VYNE) Company Profile & Facts - Yahoo …
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions.See details»
VYNE Therapeutics - Foreign Startup | Startup Nation Finder
Dec 7, 2022 · VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.See details»
Menlo Therapeutics changes name to VYNE Therapeutics
Sep 10, 2020 · “Our new corporate branding, VYNE Therapeutics, reflects an evolution of our business which combines the strengths and traditions of our legacy companies ─ Menlo …See details»
VYNE Therapeutics - VentureRadar
Website: https://vynetherapeutics.com/ Develops innovative therapies for immuno-inflammatory conditions, including proprietary treatments such as FMX114 and bromodomain & extra …See details»
VYNE Therapeutics Announces Formation of Scientific Advisory …
BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the formation of its Scientific Advisory …See details»
VYNE Therapeutics Announces FDA Clearance of IND Application …
May 6, 2024 · VYNE plans to initiate a first-in-human Phase 1a single ascending dose/multiple ascending dose (“SAD/MAD”) trial in healthy volunteers this quarter and expects to report top …See details»
Investor Overview - VYNE Therapeutics
May 17, 2022 · VYNE Therapeutics ® is a biopharmaceutical company. Committed to addressing unmet needs and providing new options for patients with immuno-inflammatory conditions.See details»
VYNE Therapeutics - Overview, News & Similar companies
View VYNE Therapeutics (www.vynetherapeutics.com) location in New Jersey, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
VYNE Stock Price Quote | Morningstar
Nov 19, 2024 · See the latest VYNE Therapeutics Inc stock price (VYNE:XNAS), related news, valuation, dividends and more to help you make your investing decisions.See details»
VYNE Therapeutics Announces the Appointment of Patrick G.
BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of …See details»
VYNE Therapeutics Announces Positive Results from Phase 1a
BRIDGEWATER, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, …See details»
VYNE Therapeutics, Inc. (VYNE Therapeutics, Inc.) - 药物管线_专利_ …
For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure …See details»
VYNE Therapeutics Inc. (VYNE) Stock Price, Quote & News - Stock …
2 days ago · Get a real-time VYNE Therapeutics Inc. (VYNE) stock price quote with breaking news, financials, statistics, charts and more.See details»
VYNE Therapeutics Reports Year-End 2021 Financial Results and …
BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing …See details»
VYNE Therapeutics Reports First Quarter 2021 Financial Results …
BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter …See details»